|
Delta DAS 6 months
|
Delta DAS 12 months
|
Delta DAS 24 months
|
Delta US GS 12 months
|
Delta US GS 24 months
|
Delta US PD 12 months
|
Delta US PD 24 months
|
Delta vdHSS T 12 months
|
Delta vdHSS T 24 months
|
---|
| |
p
| |
p
| |
p
| |
p
| |
p
| |
p
| |
p
| |
p
| |
p
|
---|
Fibβ 60–74
|
+
|
−1.9
|
0.04
|
−2.0
|
< 0.01
|
− 2. 0
|
0.02
|
− 12
|
< 0.01
|
− 13
|
< 0.01
|
−6
|
< 0.01
|
− 6
|
< 0.01
|
0.5
|
0.92
|
1.0
|
0.69
|
–
|
− 2.5
|
−2.6
|
−2.6
|
− 19
|
−21
|
−9
|
−10
|
0.5
|
1.0
|
Vim 60–75
|
+
|
−1.9
|
< 0.01
|
− 1.9
|
< 0.01
|
− 2.0
|
0.02
|
− 12
|
< 0.01
|
− 13
|
< 0.01
|
− 6
|
0.06
|
− 6
|
0.02
|
0.5
|
0.59
|
1.0
|
0.68
|
–
|
−2.6
|
− 2.6
|
− 2.6
|
−17
|
− 17
|
−8
|
−8
|
0.5
|
1.0
|
H4 31–50
|
+
|
−1.9
|
< 0.01
|
− 1.9
|
< 0.01
|
−2.0
|
< 0.01
|
− 12
|
0.05
|
− 13
|
< 0.01
|
− 6
|
0.08
|
− 6
|
0.02
|
0.5
|
0.15
|
1.0
|
0.81
|
–
|
−2.5
|
− 2.8
|
− 2.7
|
− 15
|
−17
|
−7
|
−8
|
0.5
|
1.0
|
CEP-1
|
+
|
−2.0
|
0.75
|
− 2.1
|
0.79
|
−2.1
|
0.48
|
−12
|
0.23
|
− 14
|
0.24
|
−6
|
0.17
|
−6
|
0.14
|
0.5
|
0.50
|
1.0
|
0.41
|
–
|
−2.1
|
−2.2
|
−2.0
|
−14
|
−14
|
−7
|
− 7
|
0.5
|
1.0
|
Fil 307–324
|
+
|
−1.9
|
0.01
|
−1.8
|
< 0.01
|
− 1.9
|
0.01
|
− 12
|
0.06
|
− 13
|
0.01
|
−6
|
0.03
|
−5
|
0.01
|
0.5
|
0.75
|
1.0
|
0.76
|
–
|
−2.4
|
−2.5
|
−2.5
|
−16
|
−16
|
−7
|
− 7
|
0.5
|
1.0
|
Fibα 573
|
+
|
−1.9
|
< 0.01
|
−1.8
|
< 0.01
|
− 1.9
|
< 0.01
|
− 13
|
0.36
|
− 14
|
0.12
|
−6
|
0.21
|
−6
|
0.08
|
0.5
|
0.89
|
1.0
|
0.77
|
–
|
−2.5
|
−2.6
|
−2.4
|
−13
|
−15
|
−7
|
−7
|
0.5
|
1.5
|
Fibβ 36–52
|
+
|
−1.9
|
0.02
|
−1.9
|
< 0.01
|
− 1.9
|
< 0.01
|
−12
|
0.23
|
−14
|
0.09
|
−6
|
0.08
|
−5
|
0.02
|
0.5
|
0.89
|
1.0
|
0.58
|
–
|
−2.4
|
−2.5
|
−2.5
|
−14
|
− 14
|
−7
|
−7
|
0.5
|
1.5
|
H3 1–30
|
+
|
−2.1
|
0.97
|
− 2.2
|
0.97
|
− 2.0
|
0.44
|
−12
|
0.31
|
− 13
|
0.04
|
−6
|
0.25
|
−6
|
0.09
|
0.5
|
0.24
|
1.0
|
0.45
|
–
|
−2.0
|
−2.1
|
−2.2
|
−14
|
−16
|
−7
|
−7
|
0.5
|
1.2
|
H4 14–34
|
+
|
−1.9
|
0.07
|
−2.0
|
0.12
|
−2.0
|
0.14
|
−12
|
0.46
|
−12
|
0.02
|
−7
|
0.63
|
−6
|
0.54
|
0.5
|
0.32
|
1.5
|
0.10
|
–
|
−2.1
|
−2.3
|
−2.2
|
−14
|
−16
|
−6
|
−6
|
0.5
|
1.0
|
H3 21–44
|
+
|
−2.0
|
0.48
|
−2.0
|
0.31
|
−2.0
|
0.37
|
−12
|
0.29
|
−13
|
0.39
|
−6
|
0.28
|
−6
|
0.38
|
0.5
|
0.39
|
1.5
|
0.76
|
–
|
−2.0
|
−2.2
|
−2.2
|
−15
|
−15
|
−7
|
−7
|
0.5
|
1.0
|
Fibα 621–635
|
+
|
−1.7
|
0.04
|
−1.8
|
0.04
|
−1.9
|
0.03
|
−11
|
0.02
|
−13
|
0.01
|
−6
|
0.09
|
−6
|
0.05
|
0.5
|
0.20
|
1.0
|
0.22
|
–
|
−2.3
|
−2.4
|
−2.2
|
−15
|
−16
|
−7
|
−7
|
0.5
|
1.5
|
Vim 2–17
|
+
|
−1.9
|
0.04
|
−1.8
|
0.02
|
−1.8
|
0.01
|
−12
|
0.12
|
−12
|
< 0.01
|
−6
|
0.21
|
−5
|
0.04
|
0.5
|
0.90
|
1.0
|
0.87
|
–
|
−2.2
|
−2.3
|
−2.3
|
−14
|
−16
|
−7
|
−7
|
0.5
|
1.0
|
Fibα 36–50
|
+
|
−2.0
|
0.83
|
− 2.0
|
0.74
|
− 2.0
|
0.45
|
−11
|
0.09
|
− 12
|
0.10
|
−5
|
0.02
|
−5
|
0.02
|
0.5
|
0.61
|
1.0
|
0.52
|
–
|
−2.0
|
−2.2
|
−2.2
|
−14
|
−15
|
−7
|
−7
|
0.5
|
1.0
|
Fibα 591
|
+
|
−1.9
|
0.08
|
− 1.8
|
0.03
|
− 1.8
|
0.01
|
− 13
|
0.69
|
− 16
|
0.70
|
−6
|
0.84
|
−6
|
0.77
|
0.5
|
0.41
|
1.0
|
0.58
|
–
|
−2.2
|
−2.3
|
−2.3
|
−13
|
−14
|
−6
|
−7
|
0.5
|
1.5
|
Fibβ 74
|
+
|
−1.8
|
0.41
|
−2.0
|
0.79
|
−2.1
|
0.55
|
−12
|
0.36
|
−13
|
0.94
|
−7
|
0.82
|
−7
|
0.98
|
0.5
|
0.06
|
1.5
|
0.54
|
–
|
−2.1
|
−2.2.
|
−2.0
|
−13
|
−14
|
−6
|
−6
|
0.5
|
1.0
|
Fibβ 72
|
+
|
−2.0
|
0.84
|
−2.0
|
0.73
|
−1.9
|
0.78
|
− 16
|
0.19
|
− 17
|
0.21
|
−7
|
0.13
|
−9
|
0.11
|
0.2
|
0.98
|
0.5
|
0.51
|
–
|
−2.0
|
−2.2.
|
−2.1
|
−12
|
−14
|
−6
|
−6
|
0.5
|
1.0
|
- Anti-citrullinated protein antibody (ACPA) reactivities are sorted by decreasing frequency in the cohort: p values (p) were derived from the Mann-Whitney U test; statistically significant differences are in italics
- Abbreviations: DAS Disease Activity Score (0–10), SJC swollen joint count (0–44), US ultrasound, GS grey scale (0–96), PD power Doppler 0–96), vdHSS van der Heijde modified Sharp score, T total (0–448), Fib fibrinogen, Vim vimentin, H histone, CEP-1 citrullinated enolase peptide-1, Fil filaggrin; numbers referring to amino acid sequence